Volume 34, No 9, Sep 2024

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 34 Issue 9, September 2024: 661-664   |  Open Access

LETTERS TO THE EDITOR

Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors

Xinjing Wang^1,2,3,† , Wei Wang^4,† , Siyi Zou^1,2,3,† , Zhiwei Xu^1,2,3,† , Dan Cao⁵ , Shuai Zhang⁴ , Minzhi Wei⁵ , Qian Zhan^1,2,3 , Chenlei Wen^1,2,3 , Fanlu Li^1,2,3 , Hao Chen^1,2,3 , Da Fu^1,2,3,* , Lingxi Jiang^1,2,3,* , Ming Zhao^4,* , Baiyong Shen^1,2,3,*

¹Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
²Research Institute of Pancreatic Diseases, Shanghai Key Laboratory of Translational Research for Pancreatic Neoplasms, Shanghai Jiao Tong University School of Medicine, Shanghai, China
³State Key Laboratory of Oncogenes and Related Genes, Institute of Translational Medicine, Shanghai Jiao Tong University, Shanghai, China
⁴Shanghai Xinpu BioTechnology Company Limited, Shanghai, China
⁵Hongene Biotech Corporation, Shanghai, China
^†These authors contributed equally: Xinjing Wang, Wei Wang, Siyi Zou, Zhiwei Xu
Correspondence: Da Fu(fuda@shsmu.edu.cn)Lingxi Jiang(jlx12120@rjh.com.cn)Ming Zhao(zhaoming@xinpuoncology.com)Baiyong Shen(shenby@shsmu.edu.cn)

https://doi.org/10.1038/s41422-024-00990-9

FULL TEXT | PDF

Browse 359